
Tirzepatide Delivers More Weight Loss Than Semaglutide but With More Safety Concerns
In a meta-analysis of 10 head-to-head studies including 41,381 adults with overweight or obesity, tirzepatide achieved greater weight loss and better A1c reductions than semaglutide, with about a 4.28 percentage-point greater weight loss and ~4.4 kg more weight removed, plus higher odds of reaching ≥10%, ≥15%, and ≥20% weight loss. However, serious adverse events were more frequent with tirzepatide (5.7% vs 2.9%), though discontinuations due to adverse events did not differ significantly. The analysis relied heavily on observational cohorts and followed participants for 24–72 weeks, so long-term durability and rare safety signals remain uncertain; clinicians should balance efficacy and tolerability when choosing incretin-based therapies.













